Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B-Reference-Cited by-同舟云学术

Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B

Published:2013-05-07 Issue:5 Volume:19 Page:674-678
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Lissitchkov T.¹,Matysiak M.²,Zavilska K.³,Laguna P.²,Gercheva L.⁴,Antonov A.⁵,Moret A.⁶,Caunedo P.⁶,Aznar J. A.⁶,Woodward M. K.⁷,Páez A.⁷

Affiliation:

1. National Center of Hematology; Sofia; Bulgaria

2. Department of Hematology and Oncology; Medical University; Warsaw; Poland

3. Department of Hematology and Internal Medicine; J. Strus Hospital; Poznan; Poland

4. Department of Hematology; Sveta Marina University Hospital; Varna; Bulgaria

5. Department of Hematology; University Hospital; Medical University; Pleven; Bulgaria

6. Department of Hemostasis and Thrombosis; La Fe University Hospital; Valencia; Spain

7. Department of Clinical Trials and Pharmacovigilance; Instituto Grifols S.A.; Parets del Vallès; Barcelona; Spain

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12148/fullpdf

Reference23 articles.

1. Physiological basis for transfusion therapy in hemorrhagic disorders: a critical review;Aggeler;Transfusion,1961

2. Recombinant factor IX;White;Thromb Haemost,1997

3. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B;Negrier;Blood,2011

4. Factor IX pharmacokinetics: differences between plasma-derived and recombinant products and the clinical and economic implications: a meeting report;Morfini;Haemophilia,2008

5. Implications of coagulation factor VIII and IX pharmacokinetics in the treatment of haemophilia;Collins;Haemophilia,2011

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis;Haemophilia;2022-04-14

2. Rational Clinical Dose Selection of Adeno‐Associated Virus‐Mediated Gene Therapy Based on Allometric Principles;Clinical Pharmacology & Therapeutics;2021-05-16

3. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review;Research and Practice in Thrombosis and Haemostasis;2019-05-20

4. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial;Research and Practice in Thrombosis and Haemostasis;2019-03-23

5. Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia;Therapeutic Advances in Hematology;2018-06